Digital Health Weekly Report: PomDoctor Lists on Nasdaq; Roche Expands China Footprint

Pomegranate Cloud Medical Lists on NASDAQ

On October 8, ShiLiu Cloud Medical landed on NASDAQ, becoming another listed company in the Internet medical industry. By the end of 2024, the number of contracted doctors on ShiLiu Cloud Medical reached 214,000. The platform focuses on chronic disease management with key specialties including liver disease and andrology. Among them, the retention rate of experienced doctors on the platform is 99.5%. The "doctor-brings-patient" model, along with the high retention of experienced doctors, has led to a higher patient repurchase rate, driving revenue growth. (Source: Sina Finance)

Roche to Expand Layout in China

Roche Chairman Schwan's Recent Talks with Beijing Party Secretary Yin Li and National Health Commission Director Lei Haichao Highlight Roche’s Strategic Resolve in the Chinese Market. Schwan stated that Beijing has a distinct advantage in developing its pharmaceuticals and health industry, and Roche will expand its investment and business layout in the capital. In recent years, Roche has actively positioned itself in the Chinese market, with products covering numerous medical terminals. As the global healthcare industry undergoes restructuring, the strategic value of the Chinese market becomes more prominent, further solidified by policy openness. (Source: Sina Finance)

70 Million, Wuhan IVD Company Merges with Pharmaceutical Enterprise

On October 9, 2025, Thermo Fisher Scientific Group held an extraordinary shareholders' meeting to review and approve the external investment proposal. The company will gain control of Huajiyuan Biotech, an innovative hypertension drug enterprise, through a "capital increase + equity acquisition" approach. It is expected to include Huajiyuan Biotech in its consolidated financial statements starting from 2026. Thermo Fisher Scientific will invest 42.7429 million yuan for the capital increase, raising its stake to 41%. The actual controller, Wen Wei, will invest 27.2 million yuan to acquire a 10% stake and has committed to entrusting the voting rights to Thermo Fisher Scientific, allowing it to ultimately hold 51% of the voting rights. The total investment for this transaction amounts to 69.9429 million yuan, integrating Huajiyuan Biotech's innovative drug R&D capabilities into its strategic system. (Source: Arterial Network)

Horizon Healthcare: Development of China's First Cross-Diagnostic Digital Therapy for Depression and Anxiety

After multiple rounds of product refinement and iteration, the company's efforts in this field have started to bear fruit. It has preliminarily achieved the deep integration of the latest scientific research achievements, expert clinical experience, and digital technology, and developed China’s first cross-diagnostic "digital therapy" for depression and anxiety — LotusHope. Currently, LotusHope has accumulated over 50,000 beta users, including 10,000 paying users, achieving initial scaled revenue. Chen Jizhi has unique insights into the key to the commercial success of digital therapies. He believes that "word-of-mouth" will replace "certification" as the "hard currency" for commercial success. (Source: Arterial Network)

WYTD Completes Nearly RMB100 Million Series A Financing

Recently, WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. (referred to as: WYTD) announced the completion of nearly RMB 100 million in Series A financing. This round of financing was led by Taiping Medical Health Fund, with Yangtze River Capital participating. The funds from this round will be used to accelerate the industrialization and commercialization process of a complete solution for Patent Foramen Ovale (PFO), enhance the innovative product portfolio in the field of structural heart disease, and fulfill the mission of "maximizing patients' quality of life and perfecting the last line of defense for life." (Source: Arterial Network)

LeadMed Innovation Completes Nearly 200 Million Yuan in Series B Financing

Beijing LeadMed Innovation Technology Development Co., Ltd. (hereinafter referred to as "LeadMed Innovation"), an innovative solutions provider for the neuromodulation and brain-computer interface industry chain, announced the completion of a nearly 200 million yuan Series B financing round. This round was jointly led by Shunxi Fund and Yizhuang Guotou, with participation from Galaxy Innovation Capital, Guangzhou Industrial Investment Capital, and Yizhuang Investment. Yuan Yi Capital served as the company's long-term strategic advisor. (Source: Arterial Network)

AILIAN Health Secures Over 100 Million Yuan in Financing

Wuhan Ailian Health Technology Co., Ltd. ("Ailian Health" for short) has recently completed its Series A round of financing, raising over 100 million yuan. This round of financing was led by Qianji Capital, a well-known investment institution in the healthcare field, with existing shareholder Sherpa Healthcare Partners making an oversubscribed follow-up investment. (Source: Arterial Network)

Nuoding Xianshi Completes Nearly RMB10 Million Seed Round Financing

Recently, VcBeat learned that Nuoding Xianshi Medical Technology Co., Ltd. ("Nuoding Xianshi" for short) announced the completion of nearly RMB 10 million in seed funding. This round of investment was led by well-known investment institutions and several senior professionals from the medical industry. Founded by a seasoned team with years of experience in the medical field, Nuoding Xianshi is committed to building a globally leading non-invasive, metabolism-free artificial intelligence-driven precision ultrasound plastic surgery and repair platform, focusing on helping humans resist skin aging, reshape body contours, and eliminate excess fat—all within rapidly growing sectors. (Source: VcBeat)